Vivos Inc. Extended its IsoPet® Precision Radionuclide TherapyTM to Exotics
September 30, 2024 08:30 ET
|
Vivos Inc.
Richland WA N, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. We recently treated our first exotic animal, a ferret, with encouraging results, seeing a considerable...
Vivos Inc Announces John Hopkins University as a New Regional Clinic for Isopet®
November 22, 2021 09:30 ET
|
Vivos Inc.
Richland WA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that John Hopkins University Center for Image Guided Animal Therapy (CIGAT) is now an Isopet®...
Vivos Inc Receives Feedback from FDA on Breakthrough Designation Request
January 19, 2021 09:30 ET
|
Vivos Inc.
Richland WA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Although we were unable to secure a Breakthrough Device Designation from the FDA, this was a well-designed process that...
Vivos Inc. Announces Listing to the OTCQB
September 18, 2019 07:00 ET
|
Vivos Inc.
Richland WA, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. a company engaged in the development and commercialization of minimally invasive brachytherapy treatments to...
Vivos Inc Signs a Standstill Agreement with Debt Holders Designed to Halt the Toxic Selling and Create a Debt Free Company
September 21, 2018 17:08 ET
|
Vivos Inc.
Richland WA, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Vivos, Inc. (OTC PINK: RDGL) Vivos Inc is pleased to announce that all the debtholders of Vivos convertible debt have agreed to a 10 day standstill,...
Vivos Inc Successfully Treats Canine Sarcoma with IsoPet™ (RadioGel™)
May 31, 2018 06:00 ET
|
Vivos Inc.
Richland, WA, May 31, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) successfully treated canine soft tissue sarcoma with its proprietary IsoPet™ (RadioGel™), a hydrogel liquid containing tiny...